Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 10Leukemia, Myeloid, Acute 8Neoplasm Metastasis 7Carcinoma, Renal Cell 7Myelodysplastic Syndromes 6Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Myeloproliferative Disorders 3Lung Neoplasms 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Neuroblastoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2

Interventions

Temozolomide 38Radiotherapy 22Radiosurgery 22Radiation 11Magnetic Resonance Spectroscopy 11Irinotecan 11Cyclophosphamide 11Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9pembrolizumab 8Filgrastim 8Carboplatin 8Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Lomustine 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × CTLA-4 Antigen × Clear all
NCT05341349 2026-04-23

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Emory University

Phase 1 Terminated
1 enrolled
CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡